ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1835

Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity

Elisabeth Lie1, Karen M. Fagerli2, Knut Mikkelsen3, Åse S. Lexberg4, Erik Rødevand5, Till Uhlig1 and Tore K. Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, Oslo, Norway, 3Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 4Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, 5Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since their introduction. With increasing focus on early and aggressive therapy, one could expect increasing use of biologics, including use in patients (pts) with moderate disease activity. The objectives were to examine if prescription rates of biologics in RA, PsA and AS continue to increase or have reached a plateau, and whether disease activity at initiation of therapy has changed over the years.

Methods: Data for this study were from the NOR-DMARD register. Prescriptions of biologics to biologics naïve pts with RA, PsA and AS between Jan 2002 and Nov 2011 in 4 centers covering regions in East- and Mid-Norway were studied. Population data were extracted from Statistics Norway (www.ssb.no). Prescription rates per 100,000 inhab. per year were calculated and adjusted for an estimated 15% incompleteness of the register. Numbers were also adjusted for incomplete data for 2 centers in 2002 and all centers in 2011. Further, we calculated rates as % of pts, based on published Norwegian disease prevalence data [0.45% for RA (2 studies), 0.20% for PsA, 0.26% for AS]. Baseline (BL) disease activity [CRP, DAS28 and ASDAS (from 2006)] was examined per diagnosis per year. Potential effects of prescription year were assessed by linear regression with BL variables as the dependent variable and year as a continuous (1-10) independent variable. CRP was Ln-transformed for the analyses.

Results: The material included 1961 prescriptions – 1026 in RA, 375 in PsA and 560 in AS. These were all TNF inhibitor (TNFi) prescriptions in AS, 2 non-TNFi in PsA and 38 non-TNFi in RA (32 rituximab, 3 abatacept, 3 tocilizumab). The population in the study area increased from 1.31 mill to 1.44 mill from 2002 to 2011. Prescription rates per year are shown in Table 1. There was a trend towards increasing prescription rates in AS throughout the study period. Fluctuations in the annual prescription rates were observed for RA and PsA. First biologic was since 2007 prescribed more frequently in AS and PsA together than in RA. (Table 1). BL levels of disease activity measures decreased significantly over time in all 3 diagnoses (Table 2).

Conclusion: The annual rate of first-time prescriptions of biologics to patients with RA, PsA and AS increased from 15 per 100,000 in 2003 to 25 per 100,000 in 2011. During recent years the increase was most pronounced in AS and prescriptions were more frequent in AS and PsA combined than in RA. Baseline disease activity levels at the start of treatment decreased gradually in all diseases, with a marked reduction in patients with RA.


Disclosure:

E. Lie,

Roche Pharmaceuticals,

5,

Pfizer Inc,

8;

K. M. Fagerli,

Abbott Immunology Pharmaceuticals,

8,

Pfizer Inc,

8,

Merck Pharmaceuticals,

8,

Roche Pharmaceuticals,

8;

K. Mikkelsen,
None;

S. Lexberg,

Pfizer Inc,

8,

Roche Pharmaceuticals,

8,

Merck Pharmaceuticals,

8,

Abbott Immunology Pharmaceuticals,

8;

E. Rødevand,

Abbott Immunology Pharmaceuticals,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

UCB,

5;

T. Uhlig,

Bristol-Myers Squibb,

5,

Pfizer Inc,

5,

Merck Pharmaceuticals,

5,

UCB,

5,

Roche Pharmaceuticals,

5,

Abbott Immunology Pharmaceuticals,

5;

T. K. Kvien,

Abbott Immunology Pharmaceuticals,

8,

AstraZeneca,

8,

Merck Pharmaceuticals,

8,

NiCox, S.A.,

8,

Pfizer Inc,

8,

Roche Pharmaceuticals,

8,

UCB,

8,

BMS,

5,

Abbott Immunology Pharmaceuticals,

5,

Merck Pharmaceuticals,

5,

NiCox, S.A.,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

UCB,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prescription-of-biologics-in-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-and-ankylosing-spondylitis-as-in-4-norwegian-regions-2002-2011-a-study-of-prescription-rates-and-baseline-disease-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology